The inspection has concluded successfully on 1st September 2023 without any critical/major observation
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The biosimilar Ustekinumab has been developed and manufactured by the company
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
